{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T05:56:28Z","timestamp":1770270988506,"version":"3.49.0"},"reference-count":42,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1016\/j.clml.2022.12.015","type":"journal-article","created":{"date-parts":[[2022,12,29]],"date-time":"2022-12-29T20:14:30Z","timestamp":1672344870000},"page":"203-210","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["CAR T-Cells for the Treatment of Refractory or Relapsed Large B-Cell Lymphoma: A Single-Center Retrospective Canadian Study"],"prefix":"10.1016","volume":"23","author":[{"given":"Aur\u00e9lie","family":"Benoit","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie-H\u00e9l\u00e8ne","family":"B\uff0e\u202fBoies","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicole","family":"D\u00e9ry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luciana","family":"M\uff0e\u202fGarcia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5205-652X","authenticated-orcid":false,"given":"M\u00e9lanie","family":"Simard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mireille","family":"Poirier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Delage","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara","family":"Lortal Canguilhem","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catherine","family":"Doyle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Fran\u00e7ois","family":"Larouche","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F\u00e9lix","family":"Couture","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0281-5866","authenticated-orcid":false,"given":"Christopher","family":"Lemieux","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2022.12.015_bib0001","unstructured":"Lee S. Canadian Cancer Society [Internet]. Statistics Canada and the Public Health Agency of Canada. Canadian Cancer Statistics 2021, Toronto, Ontario, Canada [access : August 18, 2022]. Available from: https:\/\/cancer.ca\/en\/research\/cancer-statistics\/canadian-cancer-statistics"},{"key":"10.1016\/j.clml.2022.12.015_bib0002","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1182\/blood-2014-05-577189","article-title":"Diffuse large B-cell lymphoma: optimizing outcome in the context of clinical and biologic heterogeneity","volume":"125","author":"Sehn","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.12.015_bib0003","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1056\/NEJM199512073332305","article-title":"Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma","volume":"333","author":"Philip","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2022.12.015_bib0004","unstructured":"INESSS [Internet]. INESSS [access: August 21, 2022]. Available from: http:\/\/www.inesss.qc.ca\/https:\/\/www.inesss.qc.ca\/fileadmin\/doc\/INESSS\/Rapports\/Therapies_cellulaires\/INESSS_Avis_Kymriah_LDGCB.pdf"},{"key":"10.1016\/j.clml.2022.12.015_bib0005","unstructured":"INESSS [Internet]. INESSS [access: August 21, 2022]. Available from: https:\/\/www.inesss.qc.ca\/publications\/repertoire-des-publications\/publication\/avis-sur-laxicabtagene-ciloleucel-pour-le-traitement-des-lymphomes-a-grandes-cellules-b-recidivants-ou-refractaires.html"},{"key":"10.1016\/j.clml.2022.12.015_bib0006","doi-asserted-by":"crossref","unstructured":"Neelapu SS, Locke FL, Bartlett NL et\u00a0al. Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma. New England Journal of Medicine 377(26):2531-44. Available from : https:\/\/doi.org\/10.1056\/nejmoa1707447","DOI":"10.1056\/NEJMoa1707447"},{"key":"10.1016\/j.clml.2022.12.015_bib0007","doi-asserted-by":"crossref","unstructured":"Schuster SJ, Bishop MR, Tam CS et\u00a0al. Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma. New England Journal of Medicine 380(1):45-56. Available from : https:\/\/doi.org\/10.1056\/nejmoa1804980","DOI":"10.1056\/NEJMoa1804980"},{"key":"10.1016\/j.clml.2022.12.015_bib0008","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1182\/blood-2017-03-769620","article-title":"Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study","volume":"130","author":"Crump","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.12.015_bib0009","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2022.12.015_bib0010","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biology of blood and marrow transplantation"},{"key":"10.1016\/j.clml.2022.12.015_bib0011","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.clml.2020.10.005","article-title":"Safety of Axicabtagene Ciloleucel for the treatment of relapsed or refractory large B-cell lymphoma","volume":"21","author":"Grana","year":"2021","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2022.12.015_bib0012","doi-asserted-by":"crossref","first-page":"3095","DOI":"10.1200\/JCO.19.02103","article-title":"Axicabtagene ciloleucel in the non-trial setting: outcomes and correlates of response, resistance, and toxicity","volume":"38","author":"Jacobson","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2022.12.015_bib0013","doi-asserted-by":"crossref","first-page":"3119","DOI":"10.1200\/JCO.19.02104","article-title":"Standard-of-care axicabtagene ciloleucel for relapsed or refractory large B-Cell lymphoma: results from the US lymphoma CAR T consortium","volume":"38","author":"Nastoupil","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2022.12.015_bib0014","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1182\/bloodadvances.2019000952","article-title":"Comparing CAR T-cell toxicity grading systems: application of the ASTCT grading system and implications for management","volume":"4","author":"Pennisi","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.clml.2022.12.015_bib0015","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1002\/ajh.25951","article-title":"Commercial anti-CD19 CAR T cell therapy for patients with relapsed\/refractory aggressive B cell lymphoma in a European center","volume":"95","author":"Sesques","year":"2020","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2022.12.015_bib0016","doi-asserted-by":"crossref","first-page":"849","DOI":"10.3389\/fonc.2020.00849","article-title":"CAR T-cell therapy for B-cell non-hodgkin lymphoma and chronic lymphocytic leukemia: clinical trials and real-world experiences","volume":"10","author":"Vitale","year":"2020","journal-title":"Front Oncol."},{"key":"10.1016\/j.clml.2022.12.015_bib0017","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1002\/ajh.26301","article-title":"Efficacy and safety of CD19-directed CAR-T cell therapies in patients with relapsed\/refractory aggressive B-cell lymphomas: Observations from the JULIET, ZUMA-1, and TRANSCEND trials","volume":"96","author":"Westin","year":"2021","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2022.12.015_bib0018","doi-asserted-by":"crossref","first-page":"3214","DOI":"10.1002\/cam4.3881","article-title":"Real-world evidence of tisagenlecleucel for the treatment of relapsed or refractory large B-cell lymphoma","volume":"10","author":"Iacoboni","year":"2021","journal-title":"Cancer Med"},{"key":"10.1016\/j.clml.2022.12.015_bib0019","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1016\/S1470-2045(21)00375-2","article-title":"Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): A multicentre, open-label, single-arm, phase 2 study","volume":"22","author":"Schuster","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2022.12.015_bib0020","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1038\/s41591-022-01969-y","article-title":"Di Blasi Ret al. A real-world comparison of tisagenlecleucel and axicabtagene ciloleucel CAR T cells in relapsed or refractory diffuse large B cell lymphoma","volume":"28","author":"Bachy","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.clml.2022.12.015_bib0021","first-page":"349","article-title":"GLA\/DRST real-world outcome analysis of CAR-T cell therapies for large B-cell lymphoma in Germany","volume":"140","author":"Bethge","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.12.015_bib0022","doi-asserted-by":"crossref","first-page":"3268","DOI":"10.1182\/bloodadvances.2020001900","article-title":"High metabolic tumor volume is associated with decreased efficacy of axicabtagene ciloleucel in large b-cell lymphoma","volume":"4","author":"Dean","year":"2020","journal-title":"Blood Adv"},{"issue":"3, Supplement","key":"10.1016\/j.clml.2022.12.015_bib0023","doi-asserted-by":"crossref","first-page":"S101","DOI":"10.1016\/j.bbmt.2019.12.603","article-title":"Earlier Steroid Use with Axicabtagene Ciloleucel (Axi-Cel) in patients with relapsed\/refractory large B cell lymphoma (R\/R LBCL)","volume":"26","author":"Topp","year":"2020","journal-title":"Biol Blood Marrow Transplant."},{"key":"10.1016\/j.clml.2022.12.015_bib0024","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1016\/j.jcyt.2017.04.001","article-title":"Monocyte lineage-derived IL-6 does not affect chimeric antigen receptor T cell function","volume":"19","author":"Singh","year":"2017","journal-title":"Cytotherapy"},{"key":"10.1016\/j.clml.2022.12.015_bib0025","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1182\/blood.V130.Suppl_1.1547.1547","article-title":"Prephylactic results of prophylactic tocilizumab after axicabtageneciloleucel (axi-cel; KTE-C19) treatment for patients with refractory,aggressive Non-Hodgkin Lymphoma (NHL)","volume":"130","author":"Locke","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.12.015_bib0026","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1200\/JCO.20.02477","article-title":"Risk-adapted preemptive tocilizumab to prevent severe cytokine release syndrome after CTL019 for pediatric B-cell acute lymphoblastic leukemia: a prospective clinical trial","volume":"39","author":"Kadauke","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2022.12.015_bib0027","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1111\/bjh.17527","article-title":"Prophylactic corticosteroid use in patients receiving axicabtagene ciloleucel for large B-cell lymphoma","volume":"194","author":"Oluwole","year":"2021","journal-title":"Brit J Haematol"},{"key":"10.1016\/j.clml.2022.12.015_bib0028","doi-asserted-by":"crossref","first-page":"6073","DOI":"10.3390\/cancers13236073","article-title":"Transformed lymphoma is associated with a favorable response to CAR-T-cell treatment in DLBCL patients","volume":"13","author":"Nydegger","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.clml.2022.12.015_bib0029","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1182\/blood-2003-05-1545","article-title":"Confirmation of molecular classification of diffuse large B-cell lymphoma by tissue microarray immunohistochemistry","volume":"103","author":"Hans","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.12.015_bib0030","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1056\/NEJMe2118899","article-title":"CAR T-cell therapy for large B-Cell lymphoma - who, when, and how?","volume":"386","author":"Roschewski","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2022.12.015_bib0031","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1051\/medsci\/2022037","article-title":"[Rest may improve CAR-T cell efficacy]","volume":"38","author":"Sroussi","year":"2022","journal-title":"Med Sci (Paris)"},{"key":"10.1016\/j.clml.2022.12.015_bib0032","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1182\/blood-2018-12-893396","article-title":"Clinical presentation, management, and biomarkers of neurotoxicity after adoptive immunotherapy with CAR T cells","volume":"133","author":"Karschnia","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.12.015_bib0033","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1056\/NEJMoa2116133","article-title":"Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma","volume":"386","author":"Locke","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2022.12.015_bib0034","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1093\/neuonc\/noaa183","article-title":"Immune effector cell-associated neurotoxicity syndrome after chimeric antigen receptor T cell therapy for lymphoma: predictive biomarkers and clinical outcomes","volume":"23","author":"Holtzman","year":"2020","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.clml.2022.12.015_bib0035","doi-asserted-by":"crossref","first-page":"5190","DOI":"10.3390\/jcm10215190","article-title":"Cytokine release syndrome in the immunotherapy of hematological malignancies: The biology behind and possible clinical consequences","volume":"10","author":"Tvedt","year":"2021","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.clml.2022.12.015_bib0036","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1182\/blood-2017-07-793760","article-title":"Infectious complications of CD19-targeted chimeric antigen receptor-modified T cell immunotherapy","volume":"131","author":"Hill","year":"2018","journal-title":"Blood."},{"key":"10.1016\/j.clml.2022.12.015_bib0037","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.3390\/cancers14061501","article-title":"Cytopenia after CAR-T cell therapy-A brief review of a complex problem","volume":"14","author":"Sharma","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.clml.2022.12.015_bib0038","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1182\/blood-2020-134816","article-title":"Predictors of Cytopenia after treatment with axicabtagene ciloleucel in patients with large cell lymphoma","volume":"136","author":"Panaite","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.12.015_bib0039","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.bbmt.2019.08.003","article-title":"Late events after treatment with CD19-targeted chimeric antigen receptor modified T cells","volume":"26","author":"Cordeiro","year":"2020","journal-title":"Biol. Blood Marrow Transplant."},{"key":"10.1016\/j.clml.2022.12.015_bib0040","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.1172\/JCI46110","article-title":"CD28 costimulation enhances the expansion and persistence of chimeric antigen receptor-modified T cells in patients with lymphoma","volume":"121","author":"Savoldo","year":"2011","journal-title":"J. Clin. Investig."},{"issue":"Suppl 4","key":"10.1016\/j.clml.2022.12.015_bib0041","article-title":"S\u00e1nchez-Escamilla Met al.How I deal with adverse effects of CAR-T cell therapy","volume":"4","author":"Y\u00e1\u00f1ez","year":"2020","journal-title":"ESMO Open"},{"key":"10.1016\/j.clml.2022.12.015_bib0042","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1182\/blood.2020010543","article-title":"CAR-HEMATOTOX: a model for CAR T-cell\u2013related hematologic toxicity in relapsed\/refractory large B-cell lymphoma","volume":"138","author":"Rejeski","year":"2021","journal-title":"Blood"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265022017797?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265022017797?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:40:58Z","timestamp":1761871258000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265022017797"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":42,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["S2152265022017797"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2022.12.015","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"CAR T-Cells for the Treatment of Refractory or Relapsed Large B-Cell Lymphoma: A Single-Center Retrospective Canadian Study","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2022.12.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}